1. Home
  2. SEVN vs IMUX Comparison

SEVN vs IMUX Comparison

Compare SEVN & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seven Hills Realty Trust

SEVN

Seven Hills Realty Trust

HOLD

Current Price

$6.17

Market Cap

167.9M

Sector

Real Estate

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$7.40

Market Cap

155.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SEVN
IMUX
Founded
1986
2016
Country
United States
United States
Employees
N/A
66
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
167.9M
155.8M
IPO Year
2008
2013

Fundamental Metrics

Financial Performance
Metric
SEVN
IMUX
Price
$6.17
$7.40
Analyst Decision
Buy
Strong Buy
Analyst Count
5
12
Target Price
$9.55
★ $43.09
AVG Volume (30 Days)
196.9K
★ 382.7K
Earning Date
10-27-2026
11-12-2026
Dividend Yield
★ 18.15%
N/A
EPS Growth
N/A
★ 38.00
EPS
★ 0.19
N/A
Revenue
★ $29,383,000.00
N/A
Revenue This Year
$18.67
N/A
Revenue Next Year
$12.98
N/A
P/E Ratio
$32.47
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$5.98
$0.51
52 Week High
$10.61
$17.43

Technical Indicators

Market Signals
Indicator
SEVN
IMUX
Relative Strength Index (RSI) 27.57 36.21
Support Level N/A $6.35
Resistance Level $8.84 $8.60
Average True Range (ATR) 0.20 0.65
MACD -0.06 0.19
Stochastic Oscillator 17.76 46.67

Price Performance

Historical Comparison
SEVN
IMUX

About SEVN Seven Hills Realty Trust

Seven Hills Realty Trust is a real estate investment trust. The company is engaged in originating and investing in floating-rate first mortgage loans secured by middle-market and transitional commercial real estate. Its primary objective is to balance capital preservation with the generation of risk-adjusted returns. The company operates in one business segment: originating and investing in floating-rate first mortgage loans secured by CRE properties.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: